Literature DB >> 35879604

Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL.

Jiexian Ma1, Shunrong Sun2, Yingwei Hu2, Min Wu2, Lin Shen2, Wulipan Fulati2, Zilan Huang2, Wensi Qian2, Pingping Chen2, Mingyue Chen2, Yanhui Xie3.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35879604     DOI： 10.1038/s41409-022-01766-8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.174


× No keyword cloud information.
  11 in total

1.  Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas.

Authors:  Sergio Cortelazzo; Corrado Tarella; Alessandro Massimo Gianni; Marco Ladetto; Anna Maria Barbui; Andrea Rossi; Giuseppe Gritti; Paolo Corradini; Massimo Di Nicola; Caterina Patti; Antonino Mulé; Manuela Zanni; Valerio Zoli; Atto Billio; Andrea Piccin; Giovanni Negri; Claudia Castellino; Francesco Di Raimondo; Andrés J M Ferreri; Fabio Benedetti; Giorgio La Nasa; Guido Gini; Livio Trentin; Maurizio Frezzato; Leonardo Flenghi; Simona Falorio; Marco Chilosi; Riccardo Bruna; Valentina Tabanelli; Stefano Pileri; Arianna Masciulli; Federica Delaini; Cristina Boschini; Alessandro Rambaldi
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

2.  Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.

Authors:  Annalisa Chiappella; Maurizio Martelli; Emanuele Angelucci; Ercole Brusamolino; Andrea Evangelista; Angelo Michele Carella; Caterina Stelitano; Giuseppe Rossi; Monica Balzarotti; Francesco Merli; Gianluca Gaidano; Vincenzo Pavone; Luigi Rigacci; Francesco Zaja; Alfonso D'Arco; Nicola Cascavilla; Eleonora Russo; Alessia Castellino; Manuel Gotti; Angela Giovanna Congiu; Maria Giuseppina Cabras; Alessandra Tucci; Claudio Agostinelli; Giovannino Ciccone; Stefano A Pileri; Umberto Vitolo
Journal:  Lancet Oncol       Date:  2017-06-28       Impact factor: 41.316

3.  Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation.

Authors:  P Galieni; E Troiani; C Bigazzi; S Mazzotta; M Ruggieri; V Pezzoni; A Dalsass; F Mestichelli; P Caraffa; F Travaglini; S Ferretti; M Angelini; S Angelini; S Falcioni
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

4.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

Authors:  T Philip; C Guglielmi; A Hagenbeek; R Somers; H Van der Lelie; D Bron; P Sonneveld; C Gisselbrecht; J Y Cahn; J L Harousseau
Journal:  N Engl J Med       Date:  1995-12-07       Impact factor: 91.245

5.  Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: Efficacy and toxicity.

Authors:  Youwu Shi; Peng Liu; Shengyu Zhou; Jianliang Yang; Xiaohong Han; Xiaohui He; Changgong Zhang; Lin Gui; Yan Qin; Sheng Yang; Liya Zhao; Jiarui Yao; Bo Jia; Shuxiang Zhang; Yan Sun; Yuankai Shi
Journal:  Asia Pac J Clin Oncol       Date:  2017-01-19       Impact factor: 2.601

6.  Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.

Authors:  Basak Oyan; Yener Koc; Evren Ozdemir; Ayse Kars; Alev Turker; Gulten Tekuzman; Emin Kansu
Journal:  Biol Blood Marrow Transplant       Date:  2005-09       Impact factor: 5.742

7.  A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.

Authors:  A Engert; R Schnell; F Küpper; M Reiser; M Engelhard; M Wilhelm; B Lathan; S Baltes-Engler; B Winterhalter; M E Scheulen; B Dederichs; H Tesch; B Wörmann; V Diehl
Journal:  Leuk Lymphoma       Date:  1997-02

8.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

Authors:  C Haioun; E Lepage; C Gisselbrecht; G Salles; B Coiffier; P Brice; A Bosly; P Morel; C Nouvel; H Tilly; P Lederlin; C Sebban; J Brière; P Gaulard; F Reyes
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

9.  Bone marrow transplantation prolongs survival after relapse in aggressive-lymphoma patients treated with the LNH-84 regimen.

Authors:  A Bosly; B Coiffier; C Gisselbrecht; H Tilly; G Auzanneau; F Andrien; R Herbrecht; M Legros; Y Devaux; J Jaubert
Journal:  J Clin Oncol       Date:  1992-10       Impact factor: 44.544

10.  Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin's lymphoma patients.

Authors:  Chen Tian; Yueyang Li; Su Liu; Zehui Chen; Yizhuo Zhang; Yong Yu; Hongliang Yang; Haifeng Zhao; Zhigang Zhao; Tian Yuan; Yafei Wang
Journal:  Sci Rep       Date:  2021-02-19       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.